Revisiting risk and benefit in early oncology trials in the era of precision medicine: A systematic review and meta-analysis of phase i trials of targeted single-agent anticancer therapies

Michael P. Mackley; Nicholas R. Fernandez; Benjamin Fletcher; Christy G. Woolcott; Conrad V. Fernandez

doi:10.1200/PO.20.00214

Revisiting risk and benefit in early oncology trials in the era of precision medicine: A systematic review and meta-analysis of phase i trials of targeted single-agent anticancer therapies

Michael P. Mackley, Nicholas R. Fernandez, Benjamin Fletcher, Christy G. Woolcott, Conrad V. Fernandez

Research output: Contribution to journal › Review article › peer-review

Original language	English
Pages (from-to)	17-26
Number of pages	10
Journal	JCO Precision Oncology
Volume	5
DOIs	https://doi.org/10.1200/PO.20.00214
Publication status	Published - 2021
Externally published	Yes

ASJC Scopus Subject Areas

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1200/PO.20.00214

Cite this

Revisiting risk and benefit in early oncology trials in the era of precision medicine: A systematic review and meta-analysis of phase i trials of targeted single-agent anticancer therapies. / Mackley, Michael P.; Fernandez, Nicholas R.; Fletcher, Benjamin et al.
In: JCO Precision Oncology, Vol. 5, 2021, p. 17-26.

Research output: Contribution to journal › Review article › peer-review

@article{90374f92063b4394936e4bfcae17a16f,

title = "Revisiting risk and benefit in early oncology trials in the era of precision medicine: A systematic review and meta-analysis of phase i trials of targeted single-agent anticancer therapies",

author = "Mackley, {Michael P.} and Fernandez, {Nicholas R.} and Benjamin Fletcher and Woolcott, {Christy G.} and Fernandez, {Conrad V.}",

note = "Funding Information: Supported by PROFYLE, Terry Fox Research Institute. M.P.M. is funded by Research In Medicine (RIM) studentship funding from the Webster studentship. C.V.F. is funded by the Department of Pediatrics, Dalhousie University. Publisher Copyright: {\textcopyright} 2021 by American Society of Clinical Oncology.",

year = "2021",

doi = "10.1200/PO.20.00214",

language = "English",

volume = "5",

pages = "17--26",

journal = "JCO Precision Oncology",

issn = "2473-4284",

publisher = "American Society of Clinical Oncology",

}

TY - JOUR

T1 - Revisiting risk and benefit in early oncology trials in the era of precision medicine

T2 - A systematic review and meta-analysis of phase i trials of targeted single-agent anticancer therapies

AU - Mackley, Michael P.

AU - Fernandez, Nicholas R.

AU - Fletcher, Benjamin

AU - Woolcott, Christy G.

AU - Fernandez, Conrad V.

N1 - Funding Information: Supported by PROFYLE, Terry Fox Research Institute. M.P.M. is funded by Research In Medicine (RIM) studentship funding from the Webster studentship. C.V.F. is funded by the Department of Pediatrics, Dalhousie University. Publisher Copyright: © 2021 by American Society of Clinical Oncology.

PY - 2021

Y1 - 2021

UR - http://www.scopus.com/inward/record.url?scp=85110105366&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85110105366&partnerID=8YFLogxK

U2 - 10.1200/PO.20.00214

DO - 10.1200/PO.20.00214

M3 - Review article

AN - SCOPUS:85110105366

SN - 2473-4284

VL - 5

SP - 17

EP - 26

JO - JCO Precision Oncology

JF - JCO Precision Oncology

ER -

Revisiting risk and benefit in early oncology trials in the era of precision medicine: A systematic review and meta-analysis of phase i trials of targeted single-agent anticancer therapies

ASJC Scopus Subject Areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this